Table 2.
Sensitivities and specificities of tests for identifying drug-resistant PTB.
| Method | Sensitivity | Specificity | Endorsed by the WHO? |
|---|---|---|---|
| Xpert | 95% (RFP)30,31 | 94.3% (RFP\INH\Km)30,31 | Yes |
| 84% (Mfx) | |||
| 83.3% (INH) | |||
| 96.2% (Mfx) | |||
| 96.2% (Km) | |||
| LPA | 100% (RFP)32–35 | 98% (RFP)32–35 | Yes |
| 92% (INH) | 99% (INH) | ||
| 80.5% (FQNs) | 100% (FQNs) | ||
| 80.7% (Km) | 99.3% (Km) | ||
| WGS | 98% (RFP)36,37 | 98% (RFP)36,37 | No |
| 97% (INH) | 93% (INH) | ||
| RNA amplification assay | 100% (RFP)38 | 97.3% (RFP)38 | No |
| Microarray | 86.1% (RFP)39 | 97.7% (RFP)39 | No |
| 79.4% (INH) | 98.7% (INH) | ||
| HRM | 89%–94% (RFP)40,41 | 99%–100% | No |
| 85% (INH-KatG) | (RFP)40,41 | ||
| 100% (INH-InhA) | 100% (INH) |
LPA: line probe assay; WGS: whole-genome sequencing; RNA: ribonucleic acid; HRM: high resolution melting; RFP: rifampicin; INH: isoniazid; Km: kanamycin; Mfx: moxifloxacin; FQNs: fluoroquinolone.
.